Format

Send to

Choose Destination
Pharmacol Ther. 2016 Jan;157:105-11. doi: 10.1016/j.pharmthera.2015.11.004. Epub 2015 Nov 22.

Non-hormonal male contraception: A review and development of an Eppin based contraceptive.

Author information

1
Department of Cell Biology & Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Eppin Pharma Inc., Chapel Hill, NC, 27514, United States. Electronic address: morand@eppin.com.
2
Department of Pharmacology, Instituto de Biociências de Botucatu, Universidade Estadual Paulista, Botucatu, SP 18618-970, Brazil.
3
Eppin Pharma Inc., Chapel Hill, NC, 27514, United States.

Abstract

Developing a non-hormonal male contraceptive requires identifying and characterizing an appropriate target and demonstrating its essential role in reproduction. Here we review the development of male contraceptive targets and the current therapeutic agents under consideration. In addition, the development of EPPIN as a target for contraception is reviewed. EPPIN is a well characterized surface protein on human spermatozoa that has an essential function in primate reproduction. EPPIN is discussed as an example of target development, testing in non-human primates, and the search for small organic compounds that mimic contraceptive antibodies; binding EPPIN and blocking sperm motility. Although many hurdles remain before the success of a non-hormonal male contraceptive, continued persistence should yield a marketable product.

KEYWORDS:

EPPIN; Male contraception; Reproductive pharmacology; Semenogelin; Sperm

PMID:
26593445
PMCID:
PMC4703502
DOI:
10.1016/j.pharmthera.2015.11.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center